Cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives were synthesized and tested as a novel class of aldose reductase (ALR2) inhibitors. Each compound was evaluated as a diastereomeric mixture, due to tautomeric equilibria in solution. The parent compound 39 exhibited a good inhibitory activity with an IC50 value of 0.85 μM, similar to that of the well-known ARI sorbinil (IC50 0.50 μM). The concurrent introduction of a halogen and a lipophilic group in the 5- and in the 1-positions, respectively, of the indole nucleus of 39, gave compound 55, cyano[5-fluoro-1-(4-methylbenzyl)-2-oxo-2,3-dihydroindol-3-yl] acetic acid, which displayed the highest activity (IC50 0.075 μM, very close to that of tolrestat IC50 0.046 μM), with a good selectivity toward ALR2 compared with aldehyde reductase (ALR1) (16.4-fold), and no appreciable inhibitory properties against sorbitol dehydrogenase (SD), or glutathione reductase (GR). The isopropyl ester 59, a prodrug of 55, was found to be almost as effective as tolrestat in preventing cataract development in severely galactosemic rats when administered as an eye drop solution. Docking simulation of 55 into a three-dimensional model of human ALR2 made it possible to formulate the hypothesis that the 2-hydroxy tautomer was the active species binding into the catalytic site of the enzyme. This was fully consistent with the structure - activity relationships within this series of cyanooxoindolylacetic acid derivatives.
|Autori:||DA SETTIMO PASSETTI F; PRIMOFIORE G; ANTONIO DA SETTIMO; CONCETTINA LA MOTTA; FRANCESCA SIMORINI; ETTORE NOVELLINO; GIOVANNI GRECO; ANTONIO LAVECCHIA; ENRICO BOLDRINI|
|Titolo:||Novel, Highly Potent Aldose Reductase Inhibitors:Cyano(2-oxo-2,3-dihydroindol-3-yl)acetic Acid Derivatives|
|Anno del prodotto:||2003|
|Digital Object Identifier (DOI):||10.1021/jm030762f|
|Appare nelle tipologie:||1.1 Articolo in rivista|